Masimo Stock Price, News & Analysis (NASDAQ:MASI)

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MASI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MASI, but not buy additional shares or sell existing shares.
View MASI analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued 12-month price objectives for Masimo's stock. Their MASI share price targets range from $81.00 to $153.00. On average, they predict the company's stock price to reach $122.00 in the next twelve months. This suggests a possible upside of 20.4% from the stock's current price.
View analysts price targets for MASI or view top-rated stocks among Wall Street analysts.

Masimo's stock was trading at $147.95 at the beginning of the year. Since then, MASI shares have decreased by 31.5% and is now trading at $101.37.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our MASI earnings forecast.

Masimo Co. (NASDAQ:MASI) posted its quarterly earnings results on Tuesday, November, 7th. The medical equipment provider reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.04. The medical equipment provider earned $478.90 million during the quarter, compared to analyst estimates of $498.73 million. Masimo had a trailing twelve-month return on equity of 14.18% and a net margin of 4.19%. The business's revenue was down 12.8% on a year-over-year basis. During the same period in the prior year, the business earned $1.00 EPS.

ETFs with the largest weight of Masimo (NASDAQ:MASI) stock in their portfolio include Harbor Health Care ETF (MEDI), Fidelity Disruptive Medicine ETF (FMED), Global X Telemedicine & Digital Health ETF (EDOC), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), First Trust Indxx Medical Devices ETF (MDEV), BlackRock Future Health ETF (BMED), SPDR S&P Kensho New Economies Composite ETF (KOMP) and iShares U.S. Medical Devices ETF (IHI).

Masimo updated its fourth quarter earnings guidance on Tuesday, November, 7th. The company provided earnings per share guidance of $0.74-$0.94 for the period, compared to the consensus earnings per share estimate of $1.34. The company issued revenue guidance of $526-$576 million, compared to the consensus revenue estimate of $613.18 million.

136 employees have rated Masimo Chief Executive Officer Joe E. Kiani on Glassdoor.com. Joe E. Kiani has an approval rating of 90% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Masimo investors own include NVIDIA (NVDA), Netflix (NFLX), Shopify (SHOP), Okta (OKTA), PayPal (PYPL), Alibaba Group (BABA), Mastercard (MA), Trade Desk (TTD), Walt Disney (DIS) and Twilio (TWLO).

Masimo's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (9.93%), Massachusetts Financial Services Co. MA (2.87%), Eminence Capital LP (1.96%), Liontrust Investment Partners LLP (1.72%), Westfield Capital Management Co. LP (1.14%) and Hawk Ridge Capital Management LP (1.07%). Insiders that own company stock include Adam Mikkelson, Anand Sampath, Craig B Reynolds, Joe E Kiani, Micah W Young and Tao Levy.
View institutional ownership trends.

Shares of MASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.